208 related articles for article (PubMed ID: 28231524)
1. Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
Wang T; Yang Z; Zhang Y; Yan W; Wang F; He L; Zhou Y; Chen L
Eur J Med Chem; 2017 Mar; 129():275-286. PubMed ID: 28231524
[TBL] [Abstract][Full Text] [Related]
2. Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes.
He LJ; Zhu YB; Fan QZ; Miao DD; Zhang SP; Liu XP; Zhang C
Bioorg Med Chem Lett; 2019 Feb; 29(4):549-555. PubMed ID: 30630717
[TBL] [Abstract][Full Text] [Related]
3. Binding patterns and structure-activity relationship of CDK8 inhibitors.
Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
[TBL] [Abstract][Full Text] [Related]
4. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.
Czodrowski P; Mallinger A; Wienke D; Esdar C; Pöschke O; Busch M; Rohdich F; Eccles SA; Ortiz-Ruiz MJ; Schneider R; Raynaud FI; Clarke PA; Musil D; Schwarz D; Dale T; Urbahns K; Blagg J; Schiemann K
J Med Chem; 2016 Oct; 59(20):9337-9349. PubMed ID: 27490956
[TBL] [Abstract][Full Text] [Related]
6. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation.
Solum E; Hansen TV; Aesoy R; Herfindal L
Bioorg Med Chem; 2020 May; 28(10):115461. PubMed ID: 32245563
[TBL] [Abstract][Full Text] [Related]
7. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors.
Xi M; Chen T; Wu C; Gao X; Wu Y; Luo X; Du K; Yu L; Cai T; Shen R; Sun H
Eur J Med Chem; 2019 Feb; 164():77-91. PubMed ID: 30594029
[TBL] [Abstract][Full Text] [Related]
8. In Search of Novel CDK8 Inhibitors by Virtual Screening.
Kumarasiri M; Teo T; Yu M; Philip S; Basnet SK; Albrecht H; Sykes MJ; Wang P; Wang S
J Chem Inf Model; 2017 Mar; 57(3):413-416. PubMed ID: 28191946
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
[TBL] [Abstract][Full Text] [Related]
10. Angel or Devil ? - CDK8 as the new drug target.
Wu D; Zhang Z; Chen X; Yan Y; Liu X
Eur J Med Chem; 2021 Mar; 213():113043. PubMed ID: 33257171
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent and selective CDK8 inhibitors through FBDD approach.
Han X; Jiang M; Zhou C; Zhou Z; Xu Z; Wang L; Mayweg AV; Niu R; Jin TG; Yang S
Bioorg Med Chem Lett; 2017 Sep; 27(18):4488-4492. PubMed ID: 28802632
[TBL] [Abstract][Full Text] [Related]
12. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors.
Zhang H; Jing L; Liu M; Goto M; Lai F; Liu X; Sheng L; Yang Y; Yang Y; Li Y; Chen X; Lee KH; Xiao Z
Eur J Med Chem; 2021 Nov; 223():113634. PubMed ID: 34147745
[TBL] [Abstract][Full Text] [Related]
13. Pyrido[2,3-b][1,5]benzoxazepin-5(6H)-one derivatives as CDK8 inhibitors.
Martínez-González S; García AB; Albarrán MI; Cebriá A; Amezquita-Alves A; García-Campos FJ; Martínez-Gago J; Martínez-Torrecuadrada J; Muñoz IG; Blanco-Aparicio C; Pastor J
Eur J Med Chem; 2020 Sep; 201():112443. PubMed ID: 32599324
[TBL] [Abstract][Full Text] [Related]
14. Discovery of CDK8/CycC Ligands with a New Virtual Screening Tool.
Chen W; Ren X; Chang CA
ChemMedChem; 2019 Jan; 14(1):107-118. PubMed ID: 30403831
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
Philip S; Kumarasiri M; Teo T; Yu M; Wang S
J Med Chem; 2018 Jun; 61(12):5073-5092. PubMed ID: 29266937
[TBL] [Abstract][Full Text] [Related]
16. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential.
Fujimoto J; Hirayama T; Hirata Y; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
Bioorg Med Chem; 2017 Jun; 25(12):3018-3033. PubMed ID: 28392276
[TBL] [Abstract][Full Text] [Related]
17. An ensemble machine learning model generates a focused screening library for the identification of CDK8 inhibitors.
Lin TE; Yen D; HuangFu WC; Wu YW; Hsu JY; Yen SC; Sung TY; Hsieh JH; Pan SL; Yang CR; Huang WJ; Hsu KC
Protein Sci; 2024 Jun; 33(6):e5007. PubMed ID: 38723187
[TBL] [Abstract][Full Text] [Related]
18. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics.
Zhang L; Cheng C; Li J; Wang L; Chumanevich AA; Porter DC; Mindich A; Gorbunova S; Roninson IB; Chen M; McInnes C
J Med Chem; 2022 Feb; 65(4):3420-3433. PubMed ID: 35114084
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.
Schiemann K; Mallinger A; Wienke D; Esdar C; Poeschke O; Busch M; Rohdich F; Eccles SA; Schneider R; Raynaud FI; Czodrowski P; Musil D; Schwarz D; Urbahns K; Blagg J
Bioorg Med Chem Lett; 2016 Mar; 26(5):1443-51. PubMed ID: 26852363
[TBL] [Abstract][Full Text] [Related]
20. A molecular dynamics investigation of CDK8/CycC and ligand binding: conformational flexibility and implication in drug discovery.
Cholko T; Chen W; Tang Z; Chang CA
J Comput Aided Mol Des; 2018 Jun; 32(6):671-685. PubMed ID: 29737445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
